Debt-to-equity in % of Inhibikase Therapeutics, Inc. from Q3 2021 to Q3 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Inhibikase Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q3 2021 to Q3 2025.
Inhibikase Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 8.33 %, a 88.7% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Inhibikase Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	8.33	-65.4	-88.7%	Sep 30, 2025
Q2 2025	9.99	-28.1	-73.8%	Jun 30, 2025
Q1 2025	11.3	-14.7	-56.5%	Mar 31, 2025
Q4 2024	15.7	-1.44	-8.41%	Dec 31, 2024
Q3 2024	73.7	+58.3	+377%	Sep 30, 2024
Q2 2024	38.1	+23.7	+165%	Jun 30, 2024
Q1 2024	26	+11.4	+78.6%	Mar 31, 2024
Q4 2023	17.1	+2.34	+15.8%	Dec 31, 2023
Q3 2023	15.5	+2.57	+19.9%	Sep 30, 2023
Q2 2023	14.4	+3.6	+33.4%	Jun 30, 2023
Q1 2023	14.5	+6.36	+77.8%	Mar 31, 2023
Q4 2022	14.8	+5.45	+58.4%	Dec 31, 2022
Q3 2022	12.9	+0.2	+1.58%	Sep 30, 2022
Q2 2022	10.8			Jun 30, 2022
Q1 2022	8.18			Mar 31, 2022
Q4 2021	9.34			Dec 31, 2021
Q3 2021	12.7			Sep 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.